TY  - JOUR
AU  - Santos, Cristina
AU  - Azuara, Daniel
AU  - Garcia-Carbonero, Rocio
AU  - Alfonso, Pilar Garcia
AU  - Carrato, Alfredo
AU  - Elez, Mª Elena
AU  - Gomez, Auxiliadora
AU  - Losa, Ferran
AU  - Montagut, Clara
AU  - Massuti, Bartomeu
AU  - Navarro, Valenti
AU  - Varela, Mar
AU  - Lopez-Doriga, Adriana
AU  - Moreno, Victor
AU  - Valladares, Manuel
AU  - Manzano, Jose Luis
AU  - Vieitez, Jose Maria
AU  - Aranda, Enrique
AU  - Sanjuan, Xavier
AU  - Tabernero, Josep
AU  - Capella, Gabriel
AU  - Salazar, Ramon
PY  - 2017
DO  - 10.1158/1535-7163.MCT-17-0153
UR  - http://hdl.handle.net/10668/11311
T2  - Molecular cancer therapeutics
AB  - In metastatic colorectal cancer (mCRC), recent studies have shown the importance to accurately quantify low-abundance mutations of the RAS pathway because anti-EGFR therapy may depend on certain mutation thresholds. We aimed to evaluate the added...
LA  - en
PB  - American Association for Cancer Research
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic agents
KW  - Antineoplastic combined chemotherapy protocols
KW  - Biomarkers, tumor
KW  - Colorectal neoplasms
KW  - DNA mutational analysis
KW  - ErbB receptors
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle aged
KW  - Molecular targeted therapy
KW  - Mutation
KW  - Neoplasm metastasis
KW  - Neoplasm staging
KW  - Prognosis
KW  - Protein kinase inhibitors
KW  - Proto-oncogene proteins B-raf
KW  - Retrospective studies
KW  - Treatment outcome
KW  - Young adult
KW  - Ras proteins
TI  - Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
TY  - Research article
VL  - 16
ER  -